Assembly Biosciences ASMB Stock
Assembly Biosciences Price Chart
Assembly Biosciences ASMB Financial and Trading Overview
| Assembly Biosciences stock price | 20.18 USD |
| Previous Close | 22.37 USD |
| Open | 22.1 USD |
| Bid | 15.95 USD x 200 |
| Ask | 25.62 USD x 200 |
| Day's Range | 19.84 - 22.1 USD |
| 52 Week Range | 19.2 - 39.71 USD |
| Volume | 499.58K USD |
| Avg. Volume | 311.3K USD |
| Market Cap | 410.88M USD |
| Beta (5Y Monthly) | 1.224 |
| PE Ratio (TTM) | 19.403847 |
| EPS (TTM) | 1.04 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.2 USD |
ASMB Valuation Measures
| Enterprise Value | 92.87M USD |
| Trailing P/E | 19.403847 |
| Forward P/E | -7.8406386 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 5.489703 |
| Price/Book (mrq) | 1.3105599 |
| Enterprise Value/Revenue | 1.241 |
| Enterprise Value/EBITDA | -10.689 |
Trading Information
Assembly Biosciences Stock Price History
| Beta (5Y Monthly) | 1.224 |
| 52-Week Change | -37.021% |
| S&P500 52-Week Change | 13.08% |
| 52 Week High | 39.71 USD |
| 52 Week Low | 19.2 USD |
| 50-Day Moving Average | 23.88 USD |
| 200-Day Moving Average | 26.91 USD |
ASMB Share Statistics
| Avg. Volume (3 month) | 311.3K USD |
| Avg. Daily Volume (10-Days) | 258.58K USD |
| Shares Outstanding | 20.36M |
| Float | 9.14M |
| Short Ratio | 13.61 |
| % Held by Insiders | 27.99% |
| % Held by Institutions | 69.91% |
| Shares Short | 3.03M |
| Short % of Float | 19.83% |
| Short % of Shares Outstanding | 14.89% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:12 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -0.055% |
| Operating Margin (ttm) | -11.75% |
| Gross Margin | 14.95% |
| EBITDA Margin | -11.60% |
Management Effectiveness
| Return on Assets (ttm) | -2.67% |
| Return on Equity (ttm) | -0.025% |
Income Statement
| Revenue (ttm) | 74.85M USD |
| Revenue Per Share (ttm) | 4.57 USD |
| Quarterly Revenue Growth (yoy) | 38.89% |
| Gross Profit (ttm) | 11.19M USD |
| EBITDA | -8688000 USD |
| Net Income Avi to Common (ttm) | -42000 USD |
| Diluted EPS (ttm) | 1.04 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 320.36M USD |
| Total Cash Per Share (mrq) | 15.73 USD |
| Total Debt (mrq) | 2.35M USD |
| Total Debt/Equity (mrq) | 0.77 USD |
| Current Ratio (mrq) | 13.989 |
| Book Value Per Share (mrq) | 15.398 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -38481000 USD |
| Levered Free Cash Flow (ttm) | -27865750 USD |
Profile of Assembly Biosciences
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | Two Tower Place |
| ZIP | 94080 |
| Phone | 833 509 4583 |
| Website | https://www.assemblybio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 73 |
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Q&A For Assembly Biosciences Stock
What is a current ASMB stock price?
Assembly Biosciences ASMB stock price today per share is 20.18 USD.
How to purchase Assembly Biosciences stock?
You can buy ASMB shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Assembly Biosciences?
The stock symbol or ticker of Assembly Biosciences is ASMB.
Which industry does the Assembly Biosciences company belong to?
The Assembly Biosciences industry is Biotechnology.
How many shares does Assembly Biosciences have in circulation?
The max supply of Assembly Biosciences shares is 20.36M.
What is Assembly Biosciences Price to Earnings Ratio (PE Ratio)?
Assembly Biosciences PE Ratio is 19.40384700 now.
What was Assembly Biosciences earnings per share over the trailing 12 months (TTM)?
Assembly Biosciences EPS is 1.04 USD over the trailing 12 months.
Which sector does the Assembly Biosciences company belong to?
The Assembly Biosciences sector is Healthcare.
Assembly Biosciences ASMB included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech Composite
IXIC
US
|
25366.09 USD — |
-0.39
|
8.86B USD — | 25068.28 USD — | 25597.23 USD — | — - | 8.86B USD — |
|
US Tech Composite Total Return
XCMP
US
|
31344.11 USD — |
-0.38
|
— — | 30976.16 USD — | 31629.69 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12491.48 USD — |
-0.35
|
— — | 12339.28 USD — | 12603.6 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1372.96 USD — |
-1.99
|
— — | 1372.67 USD — | 1394.6 USD — | — - | — — |
